Skin care composition with function of improving skin aging

Abstract

The invention relates to the technical field of cosmetics, in particular to a skin care composition with a skin aging improving function, which comprises mogroside V and a golden camellia extract. The composition can significantly reduce the expression level of aging-related SA-beta-galactosidase in human skin fibroblasts, thereby effectively inhibiting skin cell aging. Mogroside V and the camellia nitidissima extract are compounded to achieve a synergistic effect, and the anti-aging effect of the composition is remarkably superior to that of a single component. The composition is safe and non-irritant, the raw materials are natural, and the composition is suitable for various cosmetic dosage forms such as essence, face cream and facial masks.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and more specifically to a skin care composition that improves skin aging. Background Technology

[0002] Skin aging is the result of the combined effects of endogenous and exogenous factors. Endogenous aging is influenced by metabolic regulation and genetic inheritance; exogenous aging is mainly photoaging induced by ultraviolet (UV) damage, accounting for more than 80% of skin aging factors. UV radiation releases a large number of oxygen free radicals, induces inflammatory infiltration and cell apoptosis, leading to skin laxity and wrinkle formation, moisture loss, and melanin accumulation. Anti-aging has always been a hot topic in the cosmetics industry. Currently, commonly added active ingredients in anti-aging products include retinol, pro-xylane, and peptides, but these have problems such as poor stability, strong irritation, and low transdermal absorption, making them unsuitable for sensitive skin and people with special skin types. Although new technologies are gradually emerging, such as liposomes / nanotechnology, inclusion technology, and chemical modification methods, they have not yet been widely applied due to cost and technological maturity. Therefore, there is an urgent need to develop mild and highly effective anti-aging active ingredients.

[0003] Mogrosides are the hallmark components of monk fruit (Siraitia grosvenorii Swingle) and the core active ingredients related to sweetness and efficacy. Among them, mogroside V is the most abundant and has been extensively studied, exhibiting pharmacological effects such as hypoglycemic, anti-inflammatory, antioxidant, and mucosal protective properties. Golden camellia contains abundant polyphenols and flavonoids, possessing antioxidant, anti-inflammatory, and immune-enhancing effects, showing great development potential in functional foods, health products, and daily chemical products. While mogroside V and golden camellia are more commonly used in the food industry, research in the cosmetics field is limited, and no reports have been found regarding their anti-aging applications. Summary of the Invention

[0004] The purpose of this invention is to provide a skin care composition that improves skin aging, the composition comprising mogroside V and golden camellia extract.

[0005] Specifically, the weight ratio of mogroside V to Camellia chrysanthemi extract is 1:1-10.

[0006] Preferably, the weight ratio of mogroside V to Camellia chrysanthemi extract is 1:2-5.

[0007] Specifically, the mogroside V is an extract with a mogroside V content of not less than 30%.

[0008] Preferably, the mogroside V is an extract with a mogroside V content of not less than 50%.

[0009] The present invention also provides the use of the described skin care composition in the preparation of cosmetics for anti-skin aging.

[0010] Specifically, the skin care composition has a mass percentage of 0.01-5% in the cosmetic.

[0011] Specifically, the cosmetics include toners, facial oils, serums, face creams, moisturizing lotions, face masks, sunscreens, and facial cleansers.

[0012] Specifically, the cosmetics also include any one or a combination of at least two of the following: antioxidants, emollients, moisturizers, emulsifiers, thickeners, solubilizers, chelating agents, pH adjusters, solvents, preservatives, or fragrances.

[0013] Specifically, the anti-skin aging process includes reducing the expression of aging-related β-galactosidase in skin cells.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] 1. The combination of mogroside V and golden camellia described in this invention can downregulate the expression of SA-β-galactosidase, a marker of skin aging, reduce the accumulation of senescent cells, delay the decline in skin proliferation capacity, and play an effective anti-aging role.

[0016] 2. In this invention, both mogroside V and Camellia chrysanthemi extract are natural plant-derived ingredients with high safety and low irritation. Mogroside V is a food-grade ingredient with no significant toxic side effects from long-term oral or topical use; Camellia chrysanthemi has been proven to be a non-toxic plant, so there is no need to worry about skin tolerance issues (such as redness, peeling, or stinging) caused by long-term use of the combination.

[0017] 3. In this invention, mogroside V is a water-soluble component, and the golden camellia extract contains flavonoids, polysaccharides, polyphenols and other components. It has both water solubility and mild fat solubility. Both can be stably dispersed in aqueous phase, oil phase or emulsion system, and are not prone to precipitation, layering or degradation. It can be adapted to a variety of cosmetic formulations such as toner, serum, face cream, mask, and lotion. Attached Figure Description

[0018] Figure 1 Effects of different concentrations of V30 on HFF-1 cell viability after 24 h of treatment; Figure 2 Effects of different concentrations of V50 on HFF-1 cell survival after 24 h of treatment; Figure 3 Effects of different concentrations of Camellia chrysantha extract on HFF-1 cell survival after 24 h of treatment; Figure 4Microscopic staining image showing the effect of Camellia chrysantha extract on the expression of SA-β-galactosidase in HFF-1 cells induced by H2O2. Figure 5 Microscopic staining image showing the effect of the V30 and Camellia chrysantha combination on the expression of SA-β-galactosidase in HFF-1 cells induced by H2O2. Figure 6 Microscopic staining image showing the effect of the V50 and Camellia chrysantha combination on the expression of SA-β-galactosidase in HFF-1 cells induced by H2O2. Figure 7 : Quantitative statistical bar chart of SA-β-galactosidase expression level in HFF-1 cells of each experimental group. In the figure: C represents blank control group; M represents H2O2 model group; Rapa represents positive control rapamycin group; Camellia chrysantha, V30, V50 represent corresponding single use groups; V30+Camellia chrysantha and V50+Camellia chrysantha represent combination groups. Detailed Implementation

[0019] The following examples further illustrate specific implementations of the present invention, but the implementation and protection of the present invention are not limited thereto. It should be noted that any processes not specifically described in detail below are those that can be implemented or understood by those skilled in the art by referring to existing technology.

[0020] The materials and sources used in this invention include: (1) Sample Golden Camellia Extract, Mogroside V30, and Mogroside V50 (i.e., Mogroside V content is 30% and 50% respectively, hereinafter referred to as V30 and V50) (Guilin Rhein Biotechnology Co., Ltd.) (2) Main reagents PBS (MA0020, Meilun Biotechnology Co., Ltd.); DMEM high glucose medium (MA0212, Meilun Biotechnology Co., Ltd.); Cell proliferation and toxicity assay kit (MA0218, Meilun Biotechnology Co., Ltd.); Cell senescence β-galactosidase staining kit (C0602, Beyotime Biotechnology Co., Ltd.).

[0021] (3) Cells Human skin fibroblasts HFF-1 were provided by the Cell Bank / Stem Cell Bank of the Chinese Academy of Sciences.

[0022] Example 1: Preparation of skincare composition Weigh a certain amount of mogroside V (V30) and dried powder of Camellia chrysanthemi extract, mix them evenly in a dry environment at a weight ratio of 1:2, and obtain the skin care composition of the present invention.

[0023] Example 2 Preparation of skin care composition Weigh a certain amount of mogroside V (V50) and dried powder of Camellia chrysanthemi extract, mix them evenly in a dry environment at a weight ratio of 1:2, and obtain the skin care composition of the present invention.

[0024] Example 3 Preparation of skin care composition Weigh a certain amount of mogroside V (V50) and dried powder of Camellia chrysanthemi extract, mix them evenly in a dry environment at a weight ratio of 1:5, and obtain the skin care composition of the present invention.

[0025] Example 4: Formulation and application of an anti-aging essence containing mogroside V and Camellia chrysanthemi. Formula (by weight percentage): Monk fruit glycoside V: 0.5% Golden camellia extract: 1.0% Glycerin: 5.0% Propylene glycol: 3.0% Sodium hyaluronate (low molecular weight): 0.1% Disodium EDTA: 0.05% Phenoxyethanol: 0.5% Deionized water: Balance Take an appropriate amount of deionized water, add glycerol and propylene glycol in sequence, and stir magnetically for 5-8 minutes (stirring speed 50-60 r / min) until completely mixed and a transparent, turbid basic solvent system is formed. Weigh mogroside V and Camellia chrysanthemi extract, slowly add them to the base solvent, stir at 45℃ for 10-15 minutes until completely dissolved and the solution is transparent; Maintain a temperature of 45°C, then add sodium hyaluronate and disodium EDTA sequentially, stirring until fully dissolved; Cool to room temperature (25℃), adjust the pH to 5.5-6.5, let stand for 10 minutes, then add phenoxyethanol and stir for 5-8 minutes; Sterilize by filtration through a 0.22μm microporous membrane, dispense into sterile brown storage bottles, seal the stoppers, and label. Store in a cool, dry place.

[0026] Experiment 1: Detection of the toxicity of mogroside V and Camellia chrysanthemi extract to HFF-1 cells. (1) HFF-1 cell culture The cryovials containing HFF-1 cells were quickly placed in a 37°C water bath and shaken continuously to thaw them completely within 1 minute. The cell suspension was then transferred to a 1.5 mL centrifuge tube and centrifuged at 1000 r / min for 1 minute at room temperature. The supernatant was discarded, and the cells were resuspended in 1 mL of high-glucose DMEM medium. The cells were then transferred to a 10 cm medium dish, and DMEM medium containing 10% FBS and 1% antibiotics was added. The mixture was then blown around and cultured at 37°C and 5% CO2 until the cells adhered. The medium was then changed and the cells were cultured for another 1 minute. The cells were passaged when the confluence reached 80%.

[0027] (2) Paving Count HFF-1 cells at 1×10⁻⁶. 4 Cells were seeded at a density of / well in 96-well plates and incubated at 37°C in a 5% CO2 incubator for 24 h.

[0028] (3) Administration After cell adhesion, the cells were cultured in serum-free DMEM, and different concentrations of mogroside V and Camellia chrysanthemi extract were added. A blank control group was also set up, and the treatment time was 24 h.

[0029] (4) CCK-8 assay for cell viability Prepare DMEM medium containing 10% CCK-8 working solution, add 100 μL of reaction solution to each well, incubate at 37℃ for 1 h, and then detect the absorbance value at 450 nm wavelength to calculate cell viability.

[0030] (5) Data Analysis Prism software was used for graphing and data analysis. All data are expressed as mean ± SEM, n ≥ 3. ANOVA and Tunnett's test were used for comparisons among multiple groups; t-tests were used for comparisons between two groups. Compared with the control group, p <0.05, p <0.01, p A value <0.001 indicates that the difference between groups is statistically significant.

[0031] (6) Experimental results like Figures 1-3As shown, within the concentration range of 0-400 μg / mL, V30 and V50 did not significantly inhibit the survival rate of HFF-1 cells (survival rate ≥99%), indicating that they were not cytotoxic at the concentrations involved in this study. The Camellia chrysantha extract showed no significant cytotoxicity to HFF-1 cells within the concentration range of 0-200 μg / mL, demonstrating good biocompatibility. In summary, all active ingredients exhibited excellent safety at concentrations far exceeding those used in subsequent efficacy experiments, providing a reliable safety basis for the use of the compositions of this invention in cosmetics.

[0032] Experiment Example 2: Detection of the effects of mogroside V and Camellia chrysanthemi extract on the expression of SA-β-galactosidase in HFF-1 cells. (1) HFF-1 cell culture Same as Experiment 1 (1) (2) Paving HFF-1 cells were fed at a rate of 1×10 5 The wells were seeded at a density of / wells in 6-well plates and incubated at 37°C in a 5% CO2 incubator for 24 hours.

[0033] (3) Dosing and experimental grouping After cell adhesion, the cells were cultured in serum-free DMEM and grouped as shown in the table below, and then cultured at 37°C in a 5% CO2 incubator for 24 h.

[0034] Table 1 Experimental Groups

[0035] (4) SA-β-galactosidase staining experiment Discard the supernatant, wash once with PBS, add 1 mL of β-galactosidase staining and fixation solution, and fix at room temperature for 15 min; discard the fixation solution, wash the cells three times with PBS for 3 min each time; discard the PBS, add 1 mL of staining working solution to each well, and incubate overnight at 37°C; observe the expression of β-galactosidase under an optical microscope.

[0036] (5) Data Analysis β-galactosidase expression was recorded by photograph, and the images were imported into ImageJ for quantification. Prism software was used for plotting and data analysis. All data are expressed as mean ± SEM, n ≥ 3. ANOVA and Tunnett's test were used for comparisons among multiple groups; t-tests were used for comparisons between two groups. Compared with the control group, # p <0.05, ## p <0.01, ### p <0.001 was considered statistically significant; compared with the model group, p <0.05, p <0.01, p A value <0.001 indicates that the difference between groups is statistically significant.

[0037] (6) Experimental results like Figures 4-6 As shown, compared with the normal control group, the expression level of SA-β-galactosidase in the model group cells was significantly increased, indicating that the aging model was successfully established.

[0038] Quantitative analysis results ( Figure 7 The results showed that the use of mogroside V (V30 or V50) or Camellia chrysantha extract alone had a weak effect on reducing SA-β-galactosidase expression, and its expression level was still significantly higher than that of the normal control group. However, when mogroside V (V30 or V50) was combined with Camellia chrysantha extract, the SA-β-galactosidase expression level was significantly reduced compared with the model group. p The value was <0.01), and the value recovered to near normal levels. The effect of this composition was significantly better than that of the individual components used alone, clearly demonstrating the synergistic effect between the two.

[0039] In summary, the combination of mogroside V and Camellia chrysanthemi extract provided by this invention can effectively inhibit the expression of key markers of skin aging through synergistic effects, thereby exerting a clear anti-skin aging effect.

[0040] The above embodiments are merely preferred embodiments of the present invention and are only used to explain the present invention, not to limit the present invention. Any changes, substitutions, modifications, etc., made by those skilled in the art without departing from the spirit and essence of the present invention should be within the protection scope of the present invention.

Claims

1. A skincare composition with the function of improving skin aging, characterized in that, It contains mogroside V and golden camellia extract.

2. The skincare composition according to claim 1, characterized in that, The weight ratio of mogroside V to Camellia chrysanthemi extract is 1:1-10.

3. The skincare composition according to claim 2, characterized in that, The weight ratio of mogroside V to Camellia chrysanthemi extract is 1:2-5.

4. The skincare composition according to claim 1, characterized in that, The mogroside V mentioned is an extract with a mogroside V content of not less than 30%.

5. The skincare composition according to claim 1, characterized in that, The mogroside V mentioned is an extract with a mogroside V content of not less than 50%.

6. The use of the skin care composition according to any one of claims 1-5 in the preparation of cosmetics for anti-skin aging.

7. The application according to claim 6, characterized in that, The skincare composition has a mass percentage of 0.01-5% in cosmetics.

8. The application according to claim 6, characterized in that, The cosmetics include toners, facial oils, serums, face creams, moisturizers, face masks, sunscreens, and facial cleansers.

9. The application according to claim 6, characterized in that, The cosmetics also include any one or a combination of at least two of the following: antioxidants, emollients, moisturizers, emulsifiers, thickeners, solubilizers, chelating agents, pH adjusters, solvents, preservatives, or fragrances.

10. The application according to any one of claims 6-9, characterized in that, The anti-skin aging process includes reducing the expression of aging-related β-galactosidase in skin cells.

Images